(Q33612988)

28 July 2017

Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry (English)

1 reference

28 July 2017

0 references

invasive aspergillosis

1 reference

1

Johan Maertens

1 reference

28 July 2017

8

Claudio Viscoli

1 reference

28 July 2017

Gerlinde Egerer

2

1 reference

28 July 2017

Wan Shik Shin

3

1 reference

28 July 2017

Dietmar Reichert

4

1 reference

28 July 2017

Michael Stek

5

1 reference

28 July 2017

Sheenu Chandwani

6

1 reference

28 July 2017

Malathi Shivaprakash

7

1 reference

28 July 2017

Study Team CAN-DOIA

9

1 reference

28 July 2017

22 June 2010

1 reference

28 July 2017

BMC Infectious Diseases

1 reference

28 July 2017

10

1 reference

28 July 2017

182

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2334-10-182

28 July 2017

0 references

cites work

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2914768

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2914768

Caspofungin: the first in a new class of antifungal agents

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2914768

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2914768

Invasive aspergillosis in 2002: an update

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2914768

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2914768

Aspergillosis case-fatality rate: systematic review of the literature

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2914768

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

14 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2334-10-182

Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2334-10-182

Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA).

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2334-10-182

ICH harmonized tripartite guideline: Guideline for Good Clinical Practice.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2914768

Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20569436

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2334-10-182

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference